Figure 2 | Scientific Reports

Figure 2

From: Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms

Figure 2

Reversine reduces cell viability of JAK2V617F-positive cell lines. (A) Dose- and time-response cytotoxicity were analyzed by methylthiazoletetrazolium (MTT) assay for SET2 and HEL cells treated with graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) for 24, 48, and 72 hours. Values are expressed as the percentage of viable cells for each condition relative to untreated controls. Results are shown as the mean ± SD of at least four independent experiments. The p values and cell lines are indicated in the graphs; ***p < 0.0001; ANOVA test and Bonferroni post-test. (B) Apoptosis was detected by flow cytometry in SET2 and HEL cells treated with graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) for 48 hours using an annexin V/7AAD staining method. Representative dot plots are shown for each condition; the upper and lower right quadrants (Q2 plus Q3) cumulatively contain the apoptotic population (annexin V+ cells). (C) Bar graphs represent the mean ± SD of at least four independent experiments quantifying apoptotic cell death. The p values and cell lines are indicated in the graphs; * p < 0.05, ***p < 0.0001; ANOVA test and Bonferroni post-test. (D) Dose-response cytotoxicity for combined treatment was analyzed by methylthiazoletetrazolium (MTT) assay for SET2 and HEL cells treated with graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) and ruxolitinib (3, 10, 30, 100, 300, and 1000 nM) alone or in combination with each other for 48 hours. Values are expressed as the percentage of viable cells for each condition relative to untreated controls. Results are shown as the mean of at least three independent experiments.

Back to article page